Novartis ESMO Event Presentation

Benefit¹ was consistent across pre-specified subgroups² HR 95% CI All patients Previous ARPI setting Symptomatology Liver metastases at baseline Baseline PSA level 0.43 0.33, 0.54 CRPC ✓ HSPC 0.40 0.30, 0.52 0.57 0.33, 0.98 Asymptomatic or mildly symptomatic 0.40 0.30, 0.53 ✓ Symptomatic 0.51 0.32, 0.79 ✓ Yes 0.42 0.11, 1.61 ✓ No 0.43 0.33, 0.55 <median 0.42 0.29, 0.60 ≥ median 0.40 0.29, 0.56 Initial Gleason score < 6 0.55 0.10, 3.09 ≥ 6 0.42 0.32, 0.54 Baseline LDH level ≤ 260 IU/L 0.41 0.31, 0.54 > 260 IU/L 0.53 0.27, 1.07 Previous ARPI Abiraterone Enzalutamide 0.47 0.33, 0.66 0.35 0.24, 0.52 1. rPFS per BIRC HR for Pluvicto vs. ARPI change 2. Subgroups with <10 patients in both arms include liver mets at baseline (yes) and initial Gleason score < 6 16 NOVARTIS ESMO EVENT | OCTOBER 24, 2023 | INVESTOR PRESENTATION NOVARTIS | Reimagining Medicine

View entire presentation